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A large hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72, a gene located on chromosome 9p21, has
been recently reported to be responsible for 40% of familial amyotrophic lateral sclerosis cases of European ancestry. The aim
of the current article was to describe the phenotype of amyotrophic lateral sclerosis cases carrying the expansion by providing a
detailed clinical description of affected cases from representative multi-generational kindreds, and by analysing the age of onset,
gender ratio and survival in a large cohort of patients with familial amyotrophic lateral sclerosis. We collected DNA and
analysed phenotype data for 141 index Italian familial amyotrophic lateral sclerosis cases (21 of Sardinian ancestry) and 41
German index familial amyotrophic lateral sclerosis cases. Pathogenic repeat expansions were detected in 45 (37.5%) patients
from mainland Italy, 12 (57.1%) patients of Sardinian ancestry and nine (22.0%) of the 41 German index familial amyotrophic
lateral sclerosis cases. The disease was maternally transmitted in 27 (49.1%) pedigrees and paternally transmitted in 28 (50.9%)
pedigrees (P = non-significant). On average, children developed disease 7.0 years earlier than their parents [children: 55.8 years
(standard deviation 7.9), parents: 62.8 (standard deviation 10.9); P = 0.003]. Parental phenotype influenced the type of clinical
symptoms manifested by the child: of the 13 cases where the affected parent had an amyotrophic lateral sclerosis–frontotem-
poral dementia or frontotemporal dementia, the affected child also developed amyotrophic lateral sclerosis–frontotemporal
dementia in nine cases. When compared with patients carrying mutations of other amyotrophic lateral sclerosis-related
genes, those with C9ORF72 expansion had commonly a bulbar onset (42.2% compared with 25.0% among non-C9ORF72
expansion cases, P = 0.03) and cognitive impairment (46.7% compared with 9.1% among non-C9ORF72 expansion cases,
P = 0.0001). Median survival from symptom onset among cases carrying C9ORF72 repeat expansion was 3.2 years lower
than that of patients carrying TARDBP mutations (5.0 years; 95% confidence interval: 3.6–7.2) and longer than those with
FUS mutations (1.9 years; 95% confidence interval: 1.7–2.1). We conclude that C9ORF72 hexanucleotide repeat expansions
were the most frequent mutation in our large cohort of patients with familial amyotrophic lateral sclerosis of Italian, Sardinian
and German ancestry. Together with mutation of SOD1, TARDBP and FUS, mutations of C9ORF72 account for 60% of familial
amyotrophic lateral sclerosis in Italy. Patients with C9ORF72 hexanucleotide repeat expansions present some phenotypic dif-
ferences compared with patients with mutations of other genes or with unknown mutations, namely a high incidence of
bulbar-onset disease and comorbidity with frontotemporal dementia. Their pedigrees typically display a high frequency of
cases with pure frontotemporal dementia, widening the concept of familial amyotrophic lateral sclerosis.
Keywords: amyotrophic lateral sclerosis; familial ALS, C9ORF72 gene; phenotype–genotype correlation
Abbreviations: ALS = amyotrophic lateral sclerosis; C9ORF72 = chromosome 9 open reading frame 72; FTD = frontotemporal
dementia; FUS = fused in sarcoma; ITALSGEN = Italian ALS genetic consortium; SOD1 = superoxide dismutase 1; TARDBP = TAR
DNA-binding protein
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder
of adult life characterized by a progressive loss of upper and lower
motorneurons at spinal and bulbar level. Its course is invariably
fatal within 3–5 years from symptom onset, and there are current-
ly no effective therapies (Kiernan et al., 2010). Approximately
5% of the cases are familial in nature, mostly inherited in an
autosomal dominant manner (Chio` et al., 2008).
Recently, we described a large hexanucleotide (GGGGCC)
repeat expansion in the first intron of C9ORF72, a gene located
on the short arm of chromosome 9 and responsible for 40% of
familial ALS cases of European ancestry (Dejesus-Hernandez et al.,
2011; Renton et al., 2011). Although this expansion acco-
unted for an unprecedented large proportion of patients with
familial ALS, little clinical data have been reported about the
phenotypic characteristics of patients with ALS carrying this type
of mutation.
The aim of the current article was to address this gap in our
knowledge by describing the phenotype of ALS cases carrying the
expansion by providing a detailed clinical description of affected
cases from representative multi-generational kindreds, and by ana-
lysing the age of onset, gender ratio and survival in a large cohort
of patients with familial ALS. As the underlying genetic lesion was
a repeat expansion, we also examined effects of the parental
gender transmitting the mutant allele on the manifestation of
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disease in their children and analysed variation of the age of onset
in parent–child couples looking for evidence of anticipation.
Patients and methods
Patients and controls
We collected DNA and analysed phenotype data for 141 index Italian
familial ALS cases. These cases were collected thorough the Italian ALS
Genetic Consortium (ITALSGEN), which is a collaborative effort invol-
ving 15 Italian ALS centres throughout the Italian peninsula (n = 120
patients with familial ALS) and the Mediterranean island of Sardinia
(n = 21 patients with familial ALS). Of note, we previously reported
the C9ORF72 repeat expansion status for 29 of these patients in our
original article (Renton et al., 2011). A separate cohort of 41 German
index cases of familial ALS, which had been collected at the ALS centre
of the Wu¨rzburg University, was also assessed. Genetic analyses of this
cohort were also included in our original article (Renton et al., 2011).
Familial ALS was defined as the presence of at least one relative (even
more distant than first- or second-degree) affected by ALS in the
pedigree (Byrne et al., 2011).
Controls consisted of 353 neurologically healthy subjects of main-
land Italian ancestry, 166 of Sardinian ancestry and 309 of German
ancestry.
All Italian cases included in the present study were negative for
mutations in major ALS genes [superoxide dismutase 1 (SOD1), TAR
DNA-binding protein (TARDBP), fused in sarcoma (FUS), optineurin
and valosin containing protein]. The same genes, with the exception
of optineurin and valosin containing protein, were assessed in German
cases. All Italian familial ALS and most German familial ALS underwent
formal neurocognitive testing of executive function, memory/learning,
attention/concentration, language and visual–spatial functions (Strong
et al., 2008), though different batteries were used at the participating
centres. Formal tests for anxiety and depression were also used. When
applicable, test results were corrected for age and educational level.
To establish a baseline cohort for comparison with the patients with
familial ALS with the C9ORF72 pathological repeat expansion, we
identified unrelated familial ALS cases that carried mutations of the
SOD1 (n = 38), TARDBP (n = 13) or FUS (n = 6) genes. These patients
were collected in the same manner as the 141 familial ALS samples
described above, namely consecutively ascertained from the 15 centres
participating in the ITALSGEN Consortium. Cases of Sardinian ancestry
were excluded from this analysis due to the particularly high presence
of the p.A382T missense mutation of the TARDBP gene in this popu-
lation related to a founder effect (Chio` et al., 2011a). Patients with
optineurin mutations (n = 1) and valosin containing protein mutations
(n = 1) were similarly excluded from the analyses due to their low
numbers. A flow diagram reporting the numbers of patients in the
various part of the study is shown in Fig. 1.
Screening of hexanucleotide repeat
expansion of the C9ORF72 gene
A repeat-primed polymerase chain reaction assay was used to screen
the presence of the GGGGCC hexanucleotide expansion in the first
intron of C9ORF72 as described in the original article (Renton et al.,
2011). This assay rapidly and robustly determined whether a sample
carries the repeat expansion.
Statistical analysis
Differences between groups were analysed using t-tests for continuous
variables (such as age at symptom onset) and 2 for discrete variables
[such as gender, site of onset and presence of frontotemporal demen-
tia (FTD)]. Comparison between a series of means was performed with
ANOVA. Survival was calculated using Kaplan–Meier curves and the
log-rank test was used to compare survival across groups. The last day
of follow-up was 1 October 2011, and none of the patients were lost
to follow-up. A P5 0.05 was considered significant, and all tests were
two-sided. All calculations were made using SPSS software (IBM cor-
poration, version 17). The ethical committees of the participating cen-
tres approved the study, and all patients signed a written informed
consent.
Results
We screened 120 unrelated familial ALS cases from mainland Italy
and 21 unrelated familial ALS cases from Sardinia for C9ORF72
hexanucleotide repeat expansions using a repeat-primed polymer-
ase chain reaction assay. Pathogenic repeat expansions were
detected in 45 (37.5%) patients from mainland Italy and 12
(57.1%) patients of Sardinian ancestry. Nine (22.0%) of the 41
German index familial ALS cases were previously reported to carry
the repeat expansion (Renton et al., 2011).
The clinical characteristics of patients with familial ALS carrying
the C9ORF72 expansion with different ethnic origin (Italians
versus Sardinians versus Germans) are reported in Table 1. No
statistically significant differences were found in age at onset,
gender, site of onset and frequency of FTD between these cohorts.
Nearly half of the patients with ALS carrying the pathogenic
repeat expansion developed comorbid cognitive impairment
during the course of their illness (44.2%, n = 30 of 68 patients).
All of these cases presented with behavioural variant FTD. More
specifically, all patients assessed with the Frontal Systems
Behaviour Scale (Family Rating form) (Grace and Malloy, 2001)
(n = 23) had impairment in the apathy and executive domains
(median T-scores: apathy 79, range 66–91, executive dysfunction
83, range 70–94; normal value565), while the disinhibition
domain was pathological in only three patients. Patients with
ALS with C9ORF72 mutations and comorbid FTD also had patho-
logical scores in tests for executive function, such as Stroop
Colour-Word Interference Test, letter and category fluency test
and Trail Making A and B. In contrast, tests for memory function,
such as Rey Figure and Digit Span, were generally normal. Three
index cases displayed prominent delusions and hallucinations,
whereas one case presented with an acute-onset obsessive–com-
pulsive disorder.
Representative pedigrees carrying
the GGGGCC hexanucleotide repeat
expansion of C9ORF72
Figure 2 shows pedigrees that are most representative of the
phenotype and course of disease associated with the hexanucleo-
tide repeat expansion. Co-occurrence of ALS and FTD within each
kindred is noteworthy.
786 | Brain 2012: 135; 784–793 A. Chio` et al.
 at C BestaBiblioteca Centrale on M
arch 2, 2012
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
ITALS#3 pedigree
The proband (III-1) developed spinal ALS at 64 years of age and
behavioural FTD one year later. She also had sensorineural hearing
loss. She died 33 months after the onset of ALS at the age of 66
years. She carried the repeat expansion of the C9ORF72 gene.
Patient III-2 developed spinal ALS at 48 years of age. She died
24 months later, and was cognitively normal at the time of her
death. Patient III-7 presented with behavioural variant FTD, and
remains alive at the time of last follow-up, 48 months after the
onset of FTD. Patient III-9 developed spinal ALS at the age of 42
years and died 2 years later at the age of 44 years. Patient III-10
presented with spinal ALS at the age of 52 years and died at 54
years. Patient III-11 developed spinal ALS at the age of 55 years
and died at 57 years. Patient II-1 died from spinal ALS at 79 years;
disease duration is uncertain. Patient II-3 died from ALS at 57
years; disease duration is unknown. Patient II-4 had FTD at 66
years; disease duration is unknown. Patient I-1 had a progressive
motor palsy, without features of FTD. He died at 65 years; disease
duration is unknown.
ITALS#4 pedigree
The proband (III-1) developed spinal ALS at the age of 33 years
and a prominent behavioural FTD 6 months later, with vivid
hallucinations and delusions. He underwent elective tracheostomy
2 years after the onset of ALS for respiratory failure; he was still
alive 38 months after the onset of ALS. He carries the hexanucleo-
tide repeat expansion of the C9ORF72 gene. The patient’s father
(II-1) developed FTD at the age of 67 years and died 3 years
later. A paternal uncle of the proband (II-2) had FTD at the
age of 65 years and a paternal aunt had spinal ALS at the age
of 61 years.
ITALS#5 pedigree
The proband (III-1) developed spinal ALS at the age of 63 years
and died 27 months later. He carried the hexanucleotide repeat
expansion of the C9ORF72 gene. His sister (III-3) had a spinal
onset ALS at 62 years and died 37 months later. Another sister
(III-4) had FTD at the age of 62 years and died 3 years later. The
mother of the proband (II-1) died at 80 years, without signs of
ALS or FTD. A maternal aunt of the proband (II-2) had bulbar ALS
at 74 and died 12 months later.
ITALS#6 pedigree
The proband (IV-1) developed spinal onset ALS with a prominent
upper motor involvement at the age of 36 years, comorbid with
FTD. She was still alive, 8 months after the onset of ALS. She
carries the hexanucleotide repeat expansion of the C9ORF72
gene. The proband’s mother (III-1) is alive without signs of
Italian FALS without
known mutation
n=120
Sardinian FALS without
known mutation
n=21
German FALS without
known mutation
n=41
Italian FALS with
known mutation
n=57
C9ORF72
sequencing
Italians
with expansion: 45
without expansion: 75 
Sardinians
with expansion: 12
without expansion: 9 
Germans
with expansion: 9
without expansion: 32
Italians FALS assessed
for phenotype and
survival: 177
genotype-phenotype
correlation
frequency of C9ORF72 expansion
in various populations
Figure 1 Flow diagram reporting the number of patients included in the various part of the study. FALS = familial ALS.
Table 1 Comparison of clinical characteristics of Italian, Sardinian and German familial ALS cases carrying the C9ORF72
hexanucleotide repeat expansion
Variable Italian familial ALS n = 45 Sardinian familial ALS n = 12 German familial ALS n = 9 Overall n = 66
Gender (female) (%) 23 (51.1) 4 (33.3) 6 (66.7) 33 (50.0)
Site of onset (bulbar) (%) 19 (42.2) 4 (33.3) 5 (55.6) 28 (42.4)
Presence of FTD (%) 21 (46.7) 7 (58.3) 2 (22.2) 30 (45.5)
Age at onset, mean (SD) (years) 57.0 (9.5) 60.4 (7.4) 56.4 (11.5) 57.6 (9.4)
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Figure 2 Pedigrees of ALS families of patients carrying the C9ORF72 GGGGCC hexanucleotide repeat expansion of the C9ORF72 gene
(ITALS#3 to ITALS#9). Mutant alleles are shown by mt, whereas wild-type alleles are indicated by wt. Red triangles represent a diagnosis
of ALS, blue triangles represent FTD. Probands are indicated by arrows. Gender of the pedigree members is obscured to protect privacy.
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ALS or FTD. The proband’s maternal grandfather (II-1) had FTD at
the age of 72 years and died 3 years later. One of his sisters (III-4)
had bulbar ALS at the age of 67 years. The great-grandfather
(II-1) had FTD and died at 81 years. A nephew of the
great-grandfather (III-6) had bulbar ALS at the age of 59 years
and died 38 months later.
ITALS#7 pedigree
The proband (III-2) developed spinal ALS at the age of 45 years
with comorbid behavioural FTD; he also developed visual hallucin-
ations; he did not adapt to non-invasive ventilation and died
11 months after the onset of ALS. He carried the repeat expansion
of the C9ORF72 gene. His brother (III-1), who also carried the
repeat expansion, developed flail leg ALS at the age of 59 years,
without FTD and died 4 years later. The proband’s mother (II-1)
had FTD at the age of 80 years and died at 83 years. The maternal
aunt (II-2) developed FTD at the age of 78 years and is alive after
4 years. She carries the C9ORF72 repeat expansion. Her son (III-4)
is currently 44 years of age and was diagnosed with schizophrenia
at the age of 22. It was not possible to test this subject for
C9ORF72.
ITALS#8 pedigree
The proband (III-1) developed bulbar ALS at the age of 59 years
and behavioural FTD 6 months later. He carries a pathological
repeat of the C9ORF72 gene. He was still alive 16 months after
the onset of ALS. The proband’s father (II-1) had FTD at the age
of 71 years and died 3 years later. A proband’s aunt (II-2)
developed bulbar ALS at the age of 66 years and died 2 years
later, and another proband’s aunt (II-3) developed FTD at the
age of 69 years and died 4 years later. The proband’s
grandfather (III-1) developed FTD at the age of 71 years and
died 3 years later.
ITALS#9 pedigree
The proband (III-1) developed bulbar ALS comorbid with
behavioural FTD at the age of 59 years. She is alive, 40 months
after the onset of ALS–FTD. She carries the C9ORF72 repeat ex-
pansion. Her brother (III-2) developed FTD at the age of 62 years
and was still alive 30 months later. He carries the C9ORF72
repeat expansion. The proband’s father had FTD at the age of
62 years and died 5 years later. A proband’s aunt died from
FTD at the age of 65 years. The duration of the disease is
unknown.
Effect of parental gender and
phenotype
The gender of the parent transmitting the mutant allele is known
to influence the phenotype of an affected child in certain repeat
expansion diseases (Machuca-Tzili et al., 2005; Reiner et al.,
2011). To determine if such an effect existed for the C9ORF72
hexanucleotide repeat expansion, we compared the age at onset
of index cases with the age at onset of the affected mother or
father in 66 years ALS pedigrees for which data was available. Of
these, the transmitting parent had ALS in 33 years (50.0%)
kindreds, ALS–FTD in four (6.1%) kindreds and FTD in nine
(13.4%) kindreds; in one of these pedigrees, the parents of the
index case were consanguineous. In the remaining 10 (15.2%)
pedigrees, both parents of the index case died without developing
symptoms, and it was not possible to identify the transmitting
parent as there were no known cases of ALS or FTD in the earlier
generations.
Considering the 55 pedigrees in which the line of parental trans-
mission was established, the disease was maternally transmitted in
27 (49.1%) pedigrees and paternally transmitted in 28 pedigrees
(50.9%) (P = non-significant). On average, children developed dis-
ease 7.0 years earlier than their parents [children: 55.8 years (SD
7.9), parents: 62.8 (SD 10.9); P = 0.003]. Maternal or paternal
transmission had no apparent effect on age at onset of the chil-
dren (Fig. 3). In contrast, parental phenotype influenced the type
of clinical symptoms manifested by the child: of the 13 cases
where the affected parent had an ALS–FTD or FTD phenotype,
the affected child also developed ALS–FTD in nine cases. This re-
lationship was not exclusive, as the affected parent of four index
cases diagnosed with ALS–FTD did not ostensibly have cognitive
defects at the time of examination.
Phenotype of patients carrying the
C9ORF72 expansion
The clinical characteristics of patients with familial ALS carrying
the C9ORF72 expansion and those with mutations of other
Figure 3 Scatter plot of age at onset of index cases versus their
parents. Male transmitting parent is indicated by green dia-
monds and maternal transmission by blue diamonds. Regression
lines for paternal and maternal transmission data are also shown
(maternal line, r2 = 0.03, P-value = non-significant; paternal line,
r2 = 0.01, P-value = non-significant). On average, children de-
veloped disease 7.0 years earlier than their parents (see main
text). Maternal or paternal transmission had no apparent effect
on age at onset of the children.
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ALS-related genes are reported in Table 2. Bulbar-onset disease
was more common among patients with ALS with C9ORF72
hexanucleotide repeat expansions compared with patients with
ALS with mutations involving other genes (42.2% compared
with 25.0% among non-C9ORF72 expansion cases, P = 0.03).
Mean age at symptom onset was similar among patients carrying
the C9ORF72 hexanucleotide repeat expansion [median 59.0
years, interquartile range (IQR) 50.6–62.9], SOD1 mutations
(50.0 years, IQR 42.8–62.6) and TARDBP mutations (66.0 years,
IQR 58.0–70.6). In contrast, patients with FUS mutations typically
manifested symptoms at a much younger age (median 35.3 years,
IQR 30.4–39.6).
Overall, cognitive impairment was much more common in
patients with C9ORF72 hexanucleotide repeat expansion (46.7%
of cases) compared with individuals carrying mutations in other
genes or unknown mutation (9.1% of cases) (P = 0.0001).
Furthermore, psychotic symptoms (delusions and hallucinations)
were reported more commonly among patients carrying the
chromosome 9p21 repeat expansion compared with non-
expanded cases. Two index familial ALS cases with unknown
mutation had a semantic dementia variant of FTD, whereas this
form of FTD was not observed among any of the cases carrying
the pathogenic repeat expansion. Interestingly, the presence of
comorbid FTD was associated with a significantly older mean
age at symptom onset in index cases [60.6 years (SD 8.9)
among patients with ALS–FTD versus 55.2 (SD 9.0) among
patients with pure ALS phenotype, P = 0.02]. A similar pattern
was observed in the transmitting parents [72.1 years (8.9)
among parents with ALS–FTD or FTD versus 61.8 years (9.9)
among parents with pure ALS phenotype, P = 0.003]. Finally, pa-
tients with comorbid FTD had more frequent bulbar-onset disease
[17 (58.6%) versus 12 (41.4%), P = 0.05].
Median survival from symptom onset among cases carrying
C9ORF72 repeat expansion was 3.2 years [95% confidence
interval (CI): 2.9–3.4]. This was similar to the survival observed
among SOD1 cases (3.8 years; 95% CI 3.1–6.5) (Fig. 4). In con-
trast, FUS-positive ALS had the shortest median survival
(1.9 years; 95% CI 1.7–2.1), whereas TARDBP-positive disease
was associated with relatively prolonged survival (5.0 years;
95% CI 3.6–7.2).
Discussion
We found that the GGGGCC hexanucleotide repeat expansion of
the C9ORF72 gene is the most common mutation in our large
cohort of patients with familial ALS of Italian, Sardinian and
German ancestry. This confirmed our previous findings and
demonstrated the importance of this gene in the pathogenesis
of the familial form of ALS (Renton et al., 2011). Overall, the
discovery of the repeat expansion means that the genetic defect
has now been elucidated for 102 (57.6%) of our consecutive
series of 177 Italian familial ALS index cases collected across the
Italian mainland. Furthermore, the high rate of this mutation in the
isolated population of Sardinia, together with the previously
described prevalence of TARDBP mutations in the same popula-
tion (Chio` et al., 2011a), means that the cause of nearly two-
thirds of all familial ALS on this island is now explained.
The frequency of familial ALS carrying the C9ORF72 hexanu-
cleotide repeat expansions in Italy and Germany is lower than that
reported in the Finnish population (Renton et al., 2011) and simi-
lar to that of the American series (Dejesuz-Hernandez et al., 2011;
Renton et al., 2011), supporting the notion of the possible
north-European origin of the mutation.
Patients with C9ORF72 hexanucleotide repeat expansions dis-
play phenotypic differences compared with patients with muta-
tions of other genes or with unknown mutations. The most
notable difference is a significantly higher frequency of cognitive
impairment both within the index patients and within the ex-
tended kindreds (Fig. 2). Mutations in other genes, particularly
TARDBP and valosin containing protein, have been occasionally
associated with FTD syndromes (Borroni et al., 2010; Chio` et al.,
2010; Johnson et al., 2010). However, the high frequency of cog-
nitive impairment associated with the GGGGCC pathogenic repeat
expansion supports the hypothesis that the overlap between ALS
and FTD phenotypes is largely driven by the chromosome 9p21
genetic lesion (Renton et al., 2011). In this way, our genetic find-
ings confirm what was already known about the neuropathology
of ALS and FTD: these clinically disparate syndromes are charac-
terized by the mislocalization and cytoplasmic accumulation of
TDP-43 leading this group of disorders to be reclassified as
TDP43-proteinopathies (Geser et al., 2009). Indeed, the
Table 2 Gender, site of onset, frequency of cognitive impairment and median age at onset (IQR) of index mainland Italian
patients with familial ALS with different gene mutations
Gene Number of cases Gender (female) (%) Bulbar onset (%) Cognitive impairment (%) Median age at
onset (IQR)
C9ORF72 45 23 (51.1) 19 (42.2) 21 (46.7) 59.0 (50.6–62.9)
FUS 6 2 (33.3) 1 (16.7) 0 35.3 (30.4–39.6)
SOD1 38 20 (52.6) 3 (7.9) 1 (2.6) 50.0 (42.8–62.6)
TARDBP 13 4 (30.8) 4 (30.8) 4 (30.8) 66.0 (58.0-70.6)
Unknown gene 75 32 (42.7) 25 (33.3) 7 (9.3) 60.7 (53.0–68.9)
Overall 177a 81 (45.8) 52 (29.4) 32 (18.1) 58.0 (47.7–67.5)
P-value – 0.54 0.011 0.0001 0.0001
a Two index cases were not included: one with optineurin missense mutation and one with valosin containing protein missense mutation.
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neuropathological features of chromosome 9p-linked ALS/FTD
include a TDP43 proteinopathy, with the peculiar involvement of
hippocampal pyramidal neurons (Boxer et al., 2011).
In our cohort, FTD in C9ORF72 mutated cases almost invariably
presents with behavioural symptoms, and there was an absence
of cases presenting with semantic dementia or progressive
non-fluent aphasia. Moreover, we identified psychotic-like symp-
toms, such as delusions and hallucinations both in three index
cases with ALS–FTD and in several relatives within the extended
kindreds (see, for example, Pedigree ITALS#7). These findings are
consistent with previous observations of families linked to chromo-
some 9.21, where behavioural symptoms were reported to be
prominent (Morita et al., 2006; Boxer et al., 2011; Pearson
et al., 2011). The neuroanatomical substrate underlying these
psychotic symptoms is not clear, though it is noteworthy that
pathological involvement of the hippocampus is prominent in
cases carrying the C9ORF72 repeat expansion, a CNS region
that is thought to have a role in the production of psychotic-like
symptoms (Goto and Grace, 2008).
Studies on family aggregations of neurodegenerative disorders
are relatively scarce in ALS, but seem to confirm the co-occurrence
of ALS and dementia in the same families. In an article based on a
retrospective analysis of a series of 197 Irish patients with ALS and
235 general neurology controls, there was a significantly higher
risk of Parkinson’s disease and dementia in first-degree relatives of
patients with ALS compared with controls (Fallis and Hardiman,
2009). Similarly, a case control study on 635 patients with
ALS and 1616 controls in the Netherlands found a mild increase
of dementia among siblings and parents of patients with sporadic
ALS (Huisman et al., 2011). However, in both papers no distinc-
tion between the different types of dementia (in particular,
Alzheimer’s disease versus FTD) was made, making it difficult to
interpret their findings in light of our new understanding of the
genetics of chromosome 9p21-linked ALS/FTD.
The reason why C9ORF72 hexanucleotide repeat expansions
manifest as disparate ALS and FTD clinical syndromes is unknown.
It could be related to variation in the size of the GGGGCC expan-
sion, to the effect of unknown regulatory genes, or to environ-
mental causes. However, an affected child was more likely to
manifest symptoms of cognitive dysfunction if the affected
parent had a FTD or ALS–FTD phenotype (see, for example,
Pedigrees ITALS#4, ITALS#7, ITALS#8 and ITALS#9). This strongly
suggests that phenotype is being influenced by a heritable factor,
rather than by a pure stochastic event.
Familial patients with ALS with C9ORF72 gene repeat expan-
sions had nearly double the frequency of bulbar-onset disease
compared with those with mutations of other genes. This finding
is in line with the observation that bulbar onset is more frequent in
Scandinavian and north-European populations (Logroscino et al.,
2010), which have been reported to have the highest frequency of
C9ORF72 mutations (Laaksovirta et al., 2010; Mok et al., 2011).
On average, patients carrying the C9ORF72 expansion mani-
fested disease in their fifth decade of life. A similar pattern has
been observed for patients with SOD1 and TARDBP mutations.
The biological substrate underlying this late-adult onset is a matter
of speculation at present. Normal cellular ageing, environmental
exposures, other genetic variants or a combination of these factors
may play a role in determining clinical onset. However, we have
observed in our cohort that patients with ALS manifesting cogni-
tive impairment had a significantly higher age at onset. One pos-
sible explanation for this observation is that the clinical phenotype
is, at least in part, driven by the age at onset. A strong influence
of the age at onset of ALS phenotype has been already found in
sporadic ALS, with a prevalence of bulbar onset in older patients
and a prominent upper motor neuron (pyramidal) phenotype in
younger patients (Chio` et al., 2011b).
In our series, there was a trend towards an earlier age at onset
in younger generations. This 7-year difference in age of onset
between parents and children may represent anticipation, a phe-
nomenon known to occur in repeat expansion diseases, such as
Huntington’s disease and myotonic dystrophy, and may reflect
increase in the expansion size with each meiosis. Care is
required in interpreting these data, because of the relatively
small number of the cohort, and because the individual kindreds
were not sufficiently detailed to detect an effect beyond two gen-
erations (e.g. grandparent and great-grandparent generation).
Accurate measurements of the repeat expansions size by
Southern blot analysis will be required to confirm if there truly is
repeat expansion instability from generation to generation:
such analysis could not be performed in the current cohort due
to lack of sufficient quantities of DNA required for such genomic
analysis.
The likelihood of detecting the C9ORF72 repeat expansion
mutation was not related to the strength of family history of
ALS. In fact, in several pedigrees the relative affected by ALS
was more distant than a first- or second-degree relative (see, for
Figure 4 Cumulative survival probability from time of disease
onset. Comparison between patients with familial ALS with
SOD1, TARDBP and FUS genes missense mutations, hexanu-
cleotide repeat expansion of the C9ORF72 gene or unknown
genetic mutation (comparison of survival curves by log-rank
text, 2 = 28.05, df 4, P = 0.0001). Green = FUS;
blue = C9ORF72; red = SOD1; violet = TARDBP; yellow = un-
known gene. Marks are censored patients.
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example, Pedigree ITALS#6). In fact, careful examination of most
pedigrees showed that a first- or second-degree relative was more
likely to be affected by FTD, strongly supporting the motion of the
ALS–FTD continuum of disease. It also highlights the importance
(and difficulties) of obtaining a detailed family history of all neu-
rodegenerative disease from patients with ALS and argues against
current efforts to limit the definition of what is familial ALS (Byrne
et al., 2011).
The current European Federation of Neurological Society (EFNS)
guidelines clinical DNA analysis for gene mutations should only be
performed in cases with a known family history of ALS, and in
sporadic ALS cases with the characteristic phenotype of the reces-
sive D90A mutation (EFNS Task Force, 2011). The complexity of
the phenotype of pedigrees related to C9ORF72 mutations, which
include cases with pure ALS, ALS–FTD and pure FTD, challenge
the current notion of familial ALS, expanding its boundaries to
families with a single patients with ALS phenotype and relatives
with pure FTD, as exemplified by pedigree ITALS#9 of our series.
In conclusion, C9ORF72 hexanucleotide repeat expansions
represent the most frequent genetic mutation among Italian famil-
ial ALS. Together with mutation of SOD1, TARDBP and FUS,
mutations of C9ORF72 account for 60% of familial ALS in
Italy. A large number of ALS cases with C9ORF72 mutations
present a comorbid behavioural variant of FTD, sometimes asso-
ciated with hallucinations and delusions. The identification of spe-
cific phenotypes related to the different ALS genes is still in its
beginnings, but early indications are already emerging that can
aid the clinical decision-making. In particular, patients with
ALS carrying C9ORF72 repeats are characterized by a high
incidence of bulbar-onset disease and comorbidity with FTD, and
their pedigrees typically display a high frequency of cases with
pure FTD.
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